Valuation

DHRDanaher

StockNYSEUnited StatesHealth careEU retail investors: available

+2.1% today · +12.8% over a year

7/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 71% of the instruments we score

Stability, Dividend safety: among the best of its peers; priced lower than most peers. Dividend yield 0.65%.

Danaher (DHR) valuation against sector peers: P/E 38.2 (sector median 30.9), P/B 3.1, EV/EBIT 35.7, free-cash-flow yield 3.5%, P/S 6.5.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricDHRSector medianvs median
P/E38.230.9 · n=15924% above
P/B3.14.0 · n=30722% below
P/S6.54.1 · n=29956% above
EV/EBIT35.725.6 · n=14639% above
Free-cash-flow yield3.5%1.4% · n=288140% above
Dividend yield0.65%0.00% · n=362—
Return on equity8.3%−2.1% · n=308—
Return on invested capital6.6%0.6% · n=282923% above
Gross margin58.6%63.3% · n=2057% below
Net debt / EBITDA2.651.27 · n=151109% above

Value factor: 64 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co48.233.0—1.5%0.6%6/10
JNJJohnson & Johnson42.28.3—3.0%1.9%8/10
ABBVAbbVie50.3—27.73.6%2.9%6/10
MRKMerck149.58.2—4.0%2.3%8/10
UNHUnitedHealth22.43.417.16.4%2.3%10/10
TMOThermo Fisher Scientific37.84.935.72.8%0.3%9/10
AMGNAmgen26.817.523.23.8%2.1%8/10
GILDGilead Sciences—16.1—6.6%1.9%5/10
ABTAbbott40.73.832.93.5%2.8%6/10
PFEPfizer41.31.9—7.1%7.4%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 25 Sep 2026 · filed 21 Oct 2026